Renal Cell Carcinoma News

Diabetes Ups Kidney Cancer Risk in Women

Diabetes Ups Kidney Cancer Risk in Women

Women with type 2 diabetes have a 1.5-fold higher risk of renal cell carcinoma compared with non-diabetic women.

Cabozantinib Effective in Real-World Analysis for Relapsed Metastatic Renal Cell Carcinoma

Cabozantinib Effective in Real-World Analysis for Relapsed Metastatic Renal Cell Carcinoma

The phase 3 METEOR study previously demonstrated that cabozantinib significantly improved survival outcomes among patients with relapsed renal cell carcinoma.

FDA Approves Nivolumab With Ipilimumab for Renal Cell Carcinoma

FDA Approves Nivolumab With Ipilimumab for Renal Cell Carcinoma

Approval was based on results from the randomized phase 3 CheckMate-214 study.

Effects of A 2 Weeks on/1 Week Off Sunitinib Schedule in Metastatic RCC

Effects of A 2 Weeks on/1 Week Off Sunitinib Schedule in Metastatic RCC

The standard schedule is associated with AEs including grade 3 to 4 fatigue, HFS, and diarrhea.

Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma

Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma

Previous studies showed that combination therapy with nivolumab and ipilimumab has promising efficacy for various cancers, including RCC, compared with either agent alone.

Axitinib With Avelumab Shows Promise as First-Line Therapy for Renal Cell Carcinoma

Axitinib With Avelumab Shows Promise as First-Line Therapy for Renal Cell Carcinoma

Researchers enrolled 6 and 49 patients into dose-finding and dose expansion stages, respectively.

PPI, H2RA Use With Pazopanib Does Not Affect PFS, OS in Renal Cell Carcinoma

PPI, H2RA Use With Pazopanib Does Not Affect PFS, OS in Renal Cell Carcinoma

Previous studies found that an elevated pH environment leads to nearly a 40% reduction in pazopanib exposure.

Cabozantinib Superior to Sunitinib for First-Line RCC Treatment Across all Subgroups

Cabozantinib Superior to Sunitinib for First-Line RCC Treatment Across all Subgroups

Findings from the phase 2 CABOSUN study showed that, compared with sunitinib, cabozantinib improves PFS and the ORR among patients with advanced RCC.

Adjuvant Sunitinib Increases Mortality Risk Among Older Women With Renal Cell Cancer

Adjuvant Sunitinib Increases Mortality Risk Among Older Women With Renal Cell Cancer

Previous findings suggested that there were no benefits to overall survival or disease-free survival with VEGF-TKIs vs placebo.

Antibiotics May Indirectly Improve PFS Among Patients With RCC Receiving TKIs

Antibiotics May Indirectly Improve PFS Among Patients With RCC Receiving TKIs

Patients receiving VEGF-TKIs are likely to have treatment dose reductions, delays, or interruptions because of diarrhea, which occurs in about 50% of cases.

Papillary Renal Cell Carcinomas May Respond to Crizotinib

Papillary Renal Cell Carcinomas May Respond to Crizotinib

Patients with PRCC1 frequently show MET mutations. Crizotinib, a dual inhibitor of MET and ALK, has shown promising activity in MET-altered cancers.

Cabozantinib Yields Similar QoL Outcomes to Everolimus in Renal Cell Carcinoma

Cabozantinib Yields Similar QoL Outcomes to Everolimus in Renal Cell Carcinoma

The phase 3 METEOR trial demonstrated that cabozantinib prolonged PFS, OS, and ORR compared with everolimus, but the impact on QoL was not fully established.

Cabozantinib Improves OS, PFS, and ORR in Bone-metastatic RCC

Cabozantinib Improves OS, PFS, and ORR in Bone-metastatic RCC

The drug was, however, associated with a greater number of grade 3 to 4 adverse events.

Cabozantinib Approved as First-line Therapy for Advanced Renal Cell Carcinoma

Cabozantinib Approved as First-line Therapy for Advanced Renal Cell Carcinoma

The FDA based its approval on data collected from the open-label, phase 2 CABOSUN study, for which researchers randomly assigned 157 patients with RCC to receive oral cabozantinib or sunitinib.

Non-steroidal Anti-inflammatory Drugs May Improve Survival in Kidney Cancer

Non-steroidal Anti-inflammatory Drugs May Improve Survival in Kidney Cancer

A cumulative-use analysis suggests that NSAIDs, ACEis, and SSRIs improve disease-specific outcomes among patients with kidney cancer, and further that NSAIDs improve overall survival.

FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma

FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma

Thirty to 40% of patients with RCC relapse a median of 2 years after nephrectomy. The majority of relapses occur within 5 years.

Cabozantinib or Nivolumab Plus Ipilimumab as Treatment Options for Renal Cell Carcinoma

Cabozantinib or Nivolumab Plus Ipilimumab as Treatment Options for Renal Cell Carcinoma

A review of data from the CABOSUN and CheckMate-214 trials to determine the use of targeted therapy in metastatic renal cell carcinoma.

Nivolumab Improves 3-year Overall Survival in Previously Treated Renal Cell Carcinoma

Nivolumab Improves 3-year Overall Survival in Previously Treated Renal Cell Carcinoma

For CheckMate-025, 803 patients with RCC previously treated with anti-angiogenic therapy were assigned to receive IV nivolumab every 2 weeks or oral everolimus once daily.

miR-181a Overexpression May Have Tumorigenic Effects in Renal Cell Carcinoma

miR-181a Overexpression May Have Tumorigenic Effects in Renal Cell Carcinoma

Previous studies have associated miR-181a dysregulation with various cancers, such as acute lymphoblastic leukemia as well as colon, breast, and pancreatic cancers, but its role in ccRCC is unknown.

Adjuvant Sunitinib Prolongs Disease-free Survival in High-risk RCC Post-nephrectomy

Adjuvant Sunitinib Prolongs Disease-free Survival in High-risk RCC Post-nephrectomy

Patients in all subgroups who received adjuvant sunitinib had a DFS benefit compared with placebo, including patients who were at a higher risk of recurrence.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs